Comparison of Prevalence of Fibromyalgia in Axial Spondyloarthritis Patients According to ACR 1990 FM, ACR 2010 FM, AAPT 2018 FM Criteria and the Effect of Concomitant Fibromyalgia on Disease Activity, Quality of Life, Functionality and Enthesopathy

Abstract

Objectives: The aim of the study is to identify and compare prevalence of fibromyalgia (FM) in axial spondyloarthritis (axSpA) patients according to American College of Rheumatology (ACR) 1990 FM, ACR 2010 FM classification and diagnosis and (ACTTION - American Pain Society Pain Taxonomy) AAPT 2018 FM diagnosis criteria. The second aim of study is to investigate the effect of FM on axSpA disease activity, quality of life, functionality and enthesopathy. Materials and Methods: The present study was single-center cross-sectional analysis conducted on 86 axSpA (61 nr-axSpA, 25 AS) patients according to the (Assessment in Spondyloarthritis International Society) ASAS criteria. Demographic characteristics, disease duration, HLA B27 positivity, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Maastricht AS (Maastricht Ankylosing Spondylitis Enthesitis Score), AS Disease Activity Score- CRP (ASDAS-CRP), AS Disease Activity Score Sedimentation (ASDAS-ESR), Ankylosing Spondylitis Quality of Life (ASQoL) and Fibromyalgia Impact Questionnaire (FIQ) are measured. 1990 ACR and 2010 ACR FM classification, diagnosis criteria and AAPT 2018 FM diagnosis criteria were applied to all patients. Results: Seven (8.1%), 36 (41.9%), 33 (38.4%) of the patients were FM according to the 1990 ACR FM, 2010 ACR FM criteria and 2018 AAPT 2018 FM criteria, respectively. 1990 ACR FM criteria was correlated with BASFI (r=0.375, p=0.001), BASDAI (r=0.250, p=0.020), MASES (r=0.228, p=0.035), ASQol (r=0.264, p=0.014) and FIQ (r=0.321, p=0.003). 2010 ACR FM criteria was correlated with BASFI, BASMI, BASDAI, ASDAS-ESR, ASDAS-CRP, MASES, ASQoL and FIQ (r between: 0.267 and 0.666, p between: 0.001-0.013). AAPT 2018 FM criteria was correlated with BASDAI (r=0.282, p=0.008) and FIQ (r=0.263, p=0.014). Conclusions: The presence of FM negatively affects the quality of life, disease activity and functionality in axSpA patients. AAPT 2018 FM criteria practically may be used to define FM in daily practice. Concomitant FM in axSpA patients might be taken into consideration for the management of treatment.

Keywords

• Fibromyalgia
• axial spondyloarthropathy
• ankylosing spondylitis
• quality of life
• disease activity

Aksiyel Spondiloartropatide Fibromiyalji Prevalansının ACR 1990 FM, ACR 2010 FM, AAPT 2018 FM Kriterlerine Göre Karşılaştırılması ve Eşlik Eden Fibromiyaljinin Hastalık Aktivitesi, Yaşam Kalitesi, Fonsiyonalite ve Entezopatiye Etkisi

Abstract

References

1. 1. Van der Linden S, van der Heijde D. Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am. 1998;24:663-676, vii.
2. 2. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25-31.
3. 3. Stolwijk C, van Onna M, Boonen A, van Tubergen A. Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis. Arthritis Care Res (Hoboken). 2016;68:1320-1331.
4. 4. López-Medina C, Garrido-Castro JL, Castro-Jiménez J, González-Navas C, Calvo-Gutiérrez J, et al. Evaluation of quality of life in patients with axial spondyloarthritis and its association with disease activity, functionality, mobility, and structural damage. Clin Rheumatol. 2018;37:1581-1588.
5. 5. Boomershine CS. Fibromyalgia: the prototypical central sensitivity syndrome. Curr Rheumatol Rev. 2015;11:131-145.
6. 6. Marques AP, Santo ASDE, Berssaneti AA, Matsutani LA, Yuan SLK. Prevalence of fibromyalgia: literature review update. Rev Bras Reumatol Engl Ed. 2017;57:356-363. English, Portuguese.
7. 7. Topbas M, Cakirbay H, Gulec H, Akgol E, Ak I, et al. The prevalence of fibromyalgia in women aged 20-64 in Turkey. Scand J Rheumatol. 2005;34:140-144.
8. 8. Verbunt JA, Pernot DH, Smeets RJ. Disability and quality of life in patients with fibromyalgia. Health Qual Life Outcomes. 2008;6:8.

9. 9. Zhao SS, Duffield SJ, Goodson NJ. The prevalence and impact of comorbid fibromyalgia in inflammatory arthritis. Best Pract Res Clin Rheumatol. 2019;33:101423.
10. 10. Haliloglu S, Carlioglu A, Akdeniz D, Karaaslan Y, Kosar A. Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity. Rheumatol Int. 2014;34:1275-1280.
11. 11. Jones GT, Mallawaarachchi B, Shim J, Lock J, Macfarlane GJ. The prevalence of fibromyalgia in axial spondyloarthritis. Rheumatol Int. 2020;40:1581- 1591.
12. 12. Rencber N, Saglam G, Huner B, Kuru O. Presence of Fibromyalgia Syndrome and Its Relationship with Clinical Parameters in Patients with Axial Spondyloarthritis. Pain Physician. 2019;22:E579-E585.
13. 13. Baraliakos X, Regel A, Kiltz U, Menne HJ, Dybowski F, et al. Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis. Rheumatology (Oxford). 2018;57:1541-1547.
14. 14. Magrey MN, Thomas C, Khan MA. The American College of Rheumatology Fibromyalgia Criteria Are Useful in the Evaluation of Fibromyalgia Symptoms in Patients With Ankylosing Spondylitis: A Cross-Sectional Study. J Clin Rheumatol. 2020 Jul 22. Epub ahead of print.
15. 15. Sayın S, Yurdakul FG, Sivas F, Bodur H. Is fibromyalgia frequency increasing in axial spondyloarthritis? Association with fibromyalgia and biological therapies. Rheumatol Int. 2020;40:1835-1841.
16. 16. Wach J, Letroublon MC, Coury F, Tebib JG. Fibromyalgia in Spondyloarthritis: Effect on Disease Activity Assessment in Clinical Practice. J Rheumatol. 2016;43:2056-2063.
17. 17. Almodóvar R, Carmona L, Zarco P, Collantes E, González C, et al. Fibromyalgia in patients with ankylosing spondylitis: prevalence and utility of the measures of activity, function and radiological damage. Clin Exp Rheumatol. 2010;28:S33-39.
18. 18. Arnold LM, Bennett RM, Crofford LJ, Dean LE, Clauw DJ, et al. AAPT Diagnosis Criteria for Fibromyalgia. J Pain. 2019;20:611-628.
19. 19. The ACR 1990 Criteria For The Classification of Fibromyalgia a: report of the multicenter criteria committee. Wolfe F, Smythe HA, Yunus MB Arthritis Rheum 1990;33:160-172.
20. 20. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Wolfe F, et al. Arthritis Care Res. 2010;62:600-610.
21. 21. Akkoc Y, Karatepe AG, Akar S, Kirazli Y, Akkoc N. A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. Rheumatol Int. 2005;25:280-284.
22. 22. Ozer HT, Sarpel T, Gulek B, Alparslan ZN, Erken E. The Turkish version of the Bath Ankylosing Spondylitis Functional Index: reliability and validity. Clin Rheumatol. 2005;24:123-128.
23. 23. Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D; Assessment of Spondylo; Arthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:18-24.
24. 24. Duruöz M, Doward L, Turan Y, Cerrahoglu L, Yurtkuran M, Calis M, et al. Translation and validation of the Turkish version of the ankylosing spondylitis quality of life (ASQoL) Questionnaire. Rheumatol Int. 2013;33:2717-2722.
25. 25. Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int. 2000;20:9-12.
26. 26. Salaffi F, Di Carlo M, Farah S, Atzeni F, Buskila D, et al. Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Status. Rheumatology (Oxford). 2020;59:3042-3049.
27. 27. Durmaz Y, İlhanlı İ. Comparison of ankylosing spondylitis patients with and without fibromyalgia syndrome according to the disease activation scores and response to treatment. Turk J Phys Med Rehab. 2021;67:509-517.